Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
Leukemias / Lymphomas : Refractory and relapsed acute myelogenous leukemia (AML)
This is a research study for pediatric patients who have acute myeloid leukemia (AML) that has relapsed, been difficult to treat, or is a very difficult type of AML to treat. AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd out the normal cells of the bone marrow. They may flood the bloodstream and invade vital organs.
The treatment involves high doses of cancer fighting medicine called chemotherapy to destroy all of the cells in the bone marrow followed by a stem cell transplant. Stem cell transplants involve removing bone marrow cells from a healthy donor, and transferring them to the patient. Often times bone marrow testing does not identify a suitable donor within the family. In this case an unrelated person may serve as the bone marrow donor.
This study is for patients that would ordinarily be offered a stem cell transplant; it is for patients whose doctors have recommended an unrelated donor stem cell transplant because a related donor is not available or has been deemed not suitable.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Wing-Hang Leung, MD
St. Jude Children’s Research Hospital
332 North Lauderdale
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068
Referring or consulting physicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.
